Data Integrity Concerns at Philips

The Novartis case in the news is fascinating. What would Philips do in a similar situation? If they found out that during the development of one of their products there were data integrity concerns (data was falsified, the method used to test wasn't capable, samples were retested into compliance, scientists made up numbers, or changed values in notebooks to get passing results, or adjusted equipment or calculations so product couldn't fail the spec, etc) how and when would they report the concern to investors, doctors, patients, and the FDA do you think? Are there any internal policies that describe such scenarios and how to report if it is discovered? Is the business conduct line or whatever it is called effective?

 

Recommend companies rehire those they fired for being honest and put them in charge of the business conduct committee.

 

I know of a serious data integrity concern that has yet to be reported by the company. The longer it goes the worse it's going to be when it's reported. Why doesn't the board do what's right now?